Journal
JOURNAL OF PERSONALIZED MEDICINE
Volume 13, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/jpm13081234
Keywords
acute myeloid leukemia; risk stratification; drug resistance; therapy response
Ask authors/readers for more resources
Acute myeloid leukemia (AML) is a hematopoietic disorder with extremely short survival. The response to therapy and overall survival in AML patients is influenced by various patient- and tumor-associated factors, including tumor cell resistance to chemotherapeutic agents. In this study, a new prognostic scale based on multiple factors was developed to stratify AML patients and predict their treatment response and survival outcomes.
Acute myeloid leukemia (AML) is a hematopoietic disorder characterized by the malignant transformation of bone marrow-derived myeloid progenitor cells with extremely short survival. To select the optimal treatment options and predict the response to therapy, the stratification of AML patients into risk groups based on genetic factors along with clinical characteristics is carried out. Despite this thorough approach, the therapy response and disease outcome for a particular patient with AML depends on several patient- and tumor-associated factors. Among these, tumor cell resistance to chemotherapeutic agents represents one of the main obstacles for improving survival outcomes in AML patients. In our study, a new prognostic scale for the risk stratification of AML patients based on the detection of the sensitivity or resistance of tumor cells to chemotherapeutic drugs in vitro as well as MDR1 mRNA/P-glycoprotein expression, tumor origin (primary or secondary), cytogenetic abnormalities, and aberrant immunophenotype was developed. This study included 53 patients diagnosed with AML. Patients who received intensive or non-intensive induction therapy were analyzed separately. Using correlation, ROC, and Cox regression analyses, we show that the risk stratification of AML patients in accordance with the developed prognostic scale correlates well with the response to therapy and represents an independent predictive factor for the overall survival of patients with newly diagnosed AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available